Universidad Peruana Cayetano Heredia

Cost-effectiveness of ceftazidime/avibactam for infections due to carbapenem-resistant bacteria in Peru

Mostrar el registro sencillo del ítem

dc.contributor.author Bolanõs-Diáz, R.
dc.contributor.author Angles-Yanqui, E.
dc.contributor.author Perez-Lazo, G.
dc.contributor.author Sanabria-Montañez, C.
dc.date.accessioned 2022-06-01T13:53:57Z
dc.date.available 2022-06-01T13:53:57Z
dc.date.issued 2022
dc.identifier.uri https://hdl.handle.net/20.500.12866/11744
dc.description.abstract Objectives: The objective of this study was to analyse the cost-effectiveness (C-E) of ceftazidime/avibactam (CAZ/AVI)-based therapy versus colistin (COL)-based therapy for pneumonia and bacteraemia caused by carbapenem-resistant enterobacteria (CRE) adjusted to Peruvian context. Methods: A Markov decision model was extrapolated from literature to evaluate the clinical and economic consequences of CAZ/AVI-based therapy compared to COL-based therapy for a hypothetical cohort of patients with CRE pneumonia or bacteraemia according to Peruvian context. It was adopted a 5-year time horizon and a Markov-cycle length of 1 year. All patients in the model were assigned to CRE pneumonia or bacteraemia state and may transit through four different health states: Home-care, long-term care without dialysis, long-term care with dialysis or death. Key findings: Intervention with CAZ/AVI becomes progressively more cost-effective from a threshold of S/24,000 or US$ 6666 (equivalent to 1 Gross Domestic Product-per cápita [GDP-pc]). The model simulation allowed to calculate an average total cost of S/2'971,582 (US$ 825,440) for CAZ/AVI against S/2'056,488 (US$ 571.247) for COL treatment, yielding an incremental cost of S/915,094 (US$ 254,193). The cost/QALY for CAZ/AVI treatment against COL therapy approaches to S/23,154 (US$ 6432), something less than 1 annual GDP-pc. There were additional benefits associated with CAZ/AVI in the 5-year horizon, such as: 21 deaths avoided, 86 hospital days avoided, 1 CRF5 avoided and a NMB of S/6649 (US$ 1847). Conclusions: The present transferability model demonstrates the C-E of CAZ/AVI over COL for the treatment of bacteraemia and CRE pneumonia according to peruvian payment thresholds. en_US
dc.language.iso eng
dc.publisher Oxford University Press
dc.relation.ispartofseries Journal of Pharmaceutical Health Services Research
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Cost-effectiveness en_US
dc.subject Ceftazidime/avibactam en_US
dc.subject Colistin en_US
dc.subject Pneumonia en_US
dc.subject Bacteraemia en_US
dc.title Cost-effectiveness of ceftazidime/avibactam for infections due to carbapenem-resistant bacteria in Peru en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1093/jphsr/rmab015
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.01.05
dc.relation.issn 1759-8885


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas